Objective: To validate the unsupervised cluster model (USCM) developed during the first pandemic wave in a cohort of critically ill patients from the second and third pandemic waves.
Design: Observational, retrospective, multicentre study.
Setting: Intensive Care Unit (ICU).
Patients: Adult patients admitted with COVID-19 and respiratory failure during the second and third pandemic waves.
Interventions: None.
Main variables of interest: Collected data included demographic and clinical characteristics, comorbidities, laboratory tests and ICU outcomes. To validate our original USCM, we assigned a phenotype to each patient of the validation cohort. The performance of the classification was determined by Silhouette coefficient (SC) and general linear modelling. In a post-hoc analysis we developed and validated a USCM specific to the validation set. The model's performance was measured using accuracy test and area under curve (AUC) ROC.
Results: A total of 2330 patients (mean age 63 [53-82] years, 1643 (70.5%) male, median APACHE II score (12 [9-16]) and SOFA score (4 [3-6]) were included. The ICU mortality was 27.2%. The USCM classified patients into 3 clinical phenotypes: A (n = 1206 patients, 51.8%); B (n = 618 patients, 26.5%), and C (n = 506 patients, 21.7%). The characteristics of patients within each phenotype were significantly different from the original population. The SC was -0.007 and the inclusion of phenotype classification in a regression model did not improve the model performance (0.79 and 0.78 ROC for original and validation model). The post-hoc model performed better than the validation model (SC -0.08).
Conclusion: Models developed using machine learning techniques during the first pandemic wave cannot be applied with adequate performance to patients admitted in subsequent waves without prior validation.
Keywords: Aprendizaje automático; Factores de riesgo; Fenotipos; Infección grave por SARS-CoV-2; Machine Learning; Phenotypes; Prognosis; Pronóstico; Risk factors; Severe SARS-CoV-2 infection; Validación; Validation.
Copyright © 2024 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.